Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
Su Jin JeongSeung Eun LeeDong Hyun ShinIe Byung ParkHui Seung LeeKyoung-Ah KimPublished in: BMC nephrology (2021)
Only 32.9 % of T2D with CKD eligible for SGLT2i is currently treated with SGLT2i in real-world clinical practice. The older patient group and clinical inertia are the main barriers to initiate SGLT2i for eligible patients. Clinicians should change the glucocentric approach and focus on reducing renal events in T2D.